Plexus Corp.'s SEC filings document operating results, financial condition, governance matters and material corporate events for its complex product design, manufacturing and services business. Recent 8-K reports furnish quarterly and fiscal-year earnings releases and related financial information for the company's product lifecycle operations across regulated end markets.
The filings also record shareholder meeting results, including director elections, advisory executive compensation votes and auditor ratification, as well as officer transition and compensation-arrangement disclosures. These records describe formal governance actions, executive roles and recurring public-company reporting obligations for PLXS.
Plexus Corp President & CEO Todd P. Kelsey reported multiple stock transactions. On February 18, 2026, he sold a total of 5,231 shares of common stock in open-market trades at prices around $194.47, $195.59, and $196.36. A footnote states these sales were made under a Rule 10b5-1 trading plan adopted on November 20, 2025.
Following these sales, he continued to hold tens of thousands of Plexus common shares directly. On February 17, 2026, he was granted 5,576 Performance Stock Units and also exercised 18,726 PSUs, receiving the same number of common shares. Separately, 8,802 shares were withheld to cover tax obligations related to the award.
Plexus Corp. reported the results of its 2026 Annual Meeting of Shareholders held on February 18, 2026. Shareholders elected all 10 director nominees, each receiving about 24 million votes in favor plus 1,032,978 broker non-votes.
Shareholders approved, on an advisory basis, the compensation of Plexus named executive officers, with 21,498,630 votes for, 2,207,349 against, 963,489 abstentions, and 1,032,978 broker non-votes. They also ratified PricewaterhouseCoopers LLP as independent auditors for fiscal 2026 with 24,258,094 votes for, 1,427,553 against, and 16,799 abstentions.
Plexus Corp. (PLXS) President & CEO Todd P. Kelsey reported a proposed sale of 9,731 common shares, with an aggregate market value of $1,906,789.45 and an approximate sale date of February 18, 2026. Robert W. Baird & Co. is named as broker, and NASDAQ is listed as the securities exchange. The proposed sale is covered by a trading plan adopted on November 20, 2025.
Kelsey also reported selling 8,120 common shares on February 3, 2026, for gross proceeds of $1,669,880.18. Kate A. Gitter signed as Kelsey’s attorney-in-fact.
Plexus Corp. officer Oliver Mihm reported an intended sale of 9,541 common shares, with an approximate sale date of February 18, 2026 and an aggregate market value of $1,921,557.40. The shares are identified as restricted stock acquired from the issuer: 2,648 on January 22, 2021, 3,450 on January 25, 2024, and 3,443 on January 31, 2025; Morgan Stanley Smith Barney LLC is the named broker.
Earlier reported sales included 2,226 shares for gross proceeds of $442,495.41 on February 17, 2026, and 2,327 shares for gross proceeds of $333,179.86 on November 25, 2025.
Plexus Corp. insider OLIVER has filed a Form 144 indicating an intention to sell 2,226 shares of common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 02/17/2026 and an aggregate market value of 442,495.41.
The 2,226 shares were acquired on 02/11/2025 as performance shares directly from the issuer. Plexus had 26,786,466 shares outstanding at the time referenced. In the past three months, OLIVER also sold 2,327 common shares on 11/25/2025 for gross proceeds of 333,179.86.
Plexus Corp. executive Patrick J. Jermain, Exec. VP & CFO, reported multiple equity transactions in Plexus Corp. (PLXS). On 02/12/2026, he completed an open-market sale of 2,321 shares of common stock at $201.1229 per share, leaving 14,561 directly held shares afterward.
On 02/17/2026, 5,611 Performance Stock Units were exercised/converted into common stock, increasing his direct holdings to 20,172 shares. In a separate tax-related move that same day, 2,638 shares were disposed of at $195.95 to cover tax obligations, resulting in 17,534 directly held shares.
The filing also shows 3,751 shares of common stock held indirectly in the Plexus Corp. 401(k) Retirement Plan. A footnote explains that, based on company performance over a three-year period, 142.4% of the portion of fiscal 2023 Performance Stock Units tied to relative total shareholder return vested, versus a maximum opportunity of up to 150%.
Plexus Corp regional president Frank Zycinski sold his remaining common shares in an open-market trade. On 02/12/2026 he sold 1,399 shares of Plexus common stock at a weighted average price of $205.9925 per share, leaving him with 0 shares beneficially owned directly.
The sales were executed in multiple trades at prices ranging from $205.96 to $205.995 per share, with the reported figure reflecting the weighted average sale price.
Plexus Corp. has a new significant institutional holder. A regulatory disclosure shows that American Century Investment Management, American Century Companies, and the Stowers Institute for Medical Research together beneficially own 1,560,622 shares of Plexus common stock, representing 5.8% of the outstanding class as of December 31, 2025.
The group reports sole voting power over 1,426,523 shares and sole dispositive power over 1,560,622 shares. They state that the shares were acquired and are held in the ordinary course of business, not to change or influence control of Plexus.
Plexus Corp. insider plans additional stock sale under Rule 144. A holder intends to sell 2,321 shares of Plexus common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $466,806.25 and 26,786,466 shares outstanding as of the notice.
The shares to be sold were acquired as performance shares from the issuer on 02/11/2025. The filing also lists prior sales by Patrick Jermain over the past three months, including 3,587 and 4,841 common shares sold on 02/04/2026 and 02/03/2026, respectively, with gross proceeds of $732,070.83 and $987,612.41.
A shareholder of PLXS filed a Rule 144 notice to sell 1,399 shares of common stock through Morgan Stanley Smith Barney LLC on 02/12/2026 on the NASDAQ, with an aggregate market value of $288,183.51 and 26,786,466 shares outstanding.
The shares to be sold were acquired as restricted stock from the issuer, including 676 shares acquired on 01/30/2026 and additional blocks of 165 and 558 shares acquired on 01/31/2025, all listed as fully paid in cash-equivalent terms.